Anticoagulants Flashcards
Vascular injury
Platelets adhere
Tissue factor is released
Anticoagulant
Targets clotting factors/cascade
Virchows triad for thrombus formation
1) Damaged endothelium
2) Hypercoagulability: smoking, estrogen
3) slow blood flow
Arterial thrombi
Prevent/TX: antiplatelet, anticoagulant agents
Due to high blood flow
Venous thrombi
Static blood flow
High clotting factors
Prevention/tx: anticoagulants
Vitamin K factors
2, 7, 9, 10
Target major sites 2,10 are most important
UFH
Inhibit II, X equally, binds ATIII
Nonlinear dose response
Interpatient clearance variability based on weight
Easily reversible with protamine
LMWH
Inhibit II and X (more X)
Linear Dose response
Lovenox SC
Dose adjustment in renal impairment
Fondaparinux
X inhibitor
Linear dose adjustment
Once daily dosing
Contraindicated in CrCl <30
Heparin
Accelerates ATIII activity to neutralize clotting factors (Xa IIa)
Warfarin pharmacometrics
Blood levels
Inhibit vit K reductase
Synthesis rate and half-life
INR prothrombin time
Warfarin pharmacokinetics
S isomer more active than R
Highly protein bound
S-2C9 metabolism R-3A4
Inhibits vitamin K VKOR (coagulation protein production)
Vitamin K antidote if INR>10
Smoking increases clearance
Chronic alcohol increases metabolism
Overall elimination not a factor
Warfarin onset
Based on clotting factor degradation
Protein C, S limit thrombosis but degrade first place causing increased prothrombin time
1-3 weeks to reach stable INR
Warfarin inhibition
S:Fluconazole, Amiodarone
R: quinolones (levofloxacin)
Variance explained by VKOR and 2C9 differences
Warfarin INR goals
2-3 in normal patient
2.5-3.5 if prosthetic heart valve